文献速递儿童消化与营养儿童感染

婴儿期使用抑酸药和抗生素与早期儿童过敏性疾病的相关性

Association Between Use of Acid-Suppressive Medications and Antibiotics During Infancy and Allergic Diseases in Early Childhood.
PubMed 文献 · JAMA Pediatr · 2018-06-04

结果显示,使用组胺2受体拮抗剂、质子泵抑制剂或抗生素与食物过敏、药物过敏、哮喘等过敏性疾病风险升高相关。结论提示婴儿期应仅在明确临床获益时使用这些药物。

要点

  • 婴儿6个月内使用H2RA或PPI与食物过敏、药物过敏、过敏性鼻炎、哮喘风险升高相关。
  • 婴儿6个月内使用抗生素与哮喘、过敏性鼻炎、过敏反应、过敏性结膜炎风险升高相关。
  • 婴儿期抑酸药和抗生素应仅在明确临床获益时使用。

核心结论

  • 婴儿出生后6个月内使用抑酸药或抗生素与早期儿童过敏性疾病的发生存在关联。

研究设计与样本

  • 儿童需从出生35天内持续入组至至少1岁,排除初始住院超过7天或出生6个月内诊断任何结局过敏性疾病者。
  • 暴露定义为配发任何H2RA、PPI或抗生素处方,主要结局为食物过敏、过敏反应、哮喘、特应性皮炎、过敏性鼻炎、过敏性结膜炎、荨麻疹、接触性皮炎、药物过敏或其他过敏。

主要发现

  • H2RA和PPI使用者的食物过敏aHR分别为2.18(95%CI 2.04-2.33)和2.59(95%CI 2.25-3.00)。
  • H2RA和PPI使用者的药物过敏aHR分别为1.70(95%CI 1.60-1.80)和1.84(95%CI 1.56-2.17),过敏反应aHR分别为1.51(95%CI 1.38-1.66)和1.45(95%CI 1.22-1.73)。
  • H2RA和PPI使用者的过敏性鼻炎aHR分别为1.50(95%CI 1.46-1.54)和1.44(95%CI 1.36-1.52),哮喘aHR分别为1.25(95%CI 1.21-1.29)和1.41(95%CI 1.31-1.52)。
  • 抗生素使用者的哮喘aHR为2.09(95%CI 2.05-2.13),过敏性鼻炎aHR为1.75(95%CI 1.72-1.78),过敏反应aHR为1.51(95%CI 1.38-1.66),过敏性结膜炎aHR为1.42(95%CI 1.34-1.50)。

关键数值与推荐

  • 婴儿期使用抑酸药和抗生素应仅在明确临床获益时使用。

临床怎么用

  • 对婴儿期考虑使用抑酸药或抗生素时,应严格评估明确临床获益,并权衡后续过敏性疾病风险。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: Allergic diseases are prevalent in childhood. Early exposure to medications that can alter the microbiome, including acid-suppressive medications and antibiotics, may influence the likelihood of allergy. OBJECTIVE: To determine whether there is an association between the use of acid-suppressive medications or antibiotics in the first 6 months of infancy and development of allergic diseases in early childhood. DESIGN, SETTING, AND PARTICIPANTS: A retrospective cohort study was conducted in 792 130 children who were Department of Defense TRICARE beneficiaries with a birth medical record in the Military Health System database between October 1, 2001, and September 30, 2013, with continued enrollment from within 35 days of birth until at least age 1 year. Children who had an initial birth stay of greater than 7 days or were diagnosed with any of the outcome allergic conditions within the first 6 months of life were excluded from the study. Data analysis was performed from April 15, 2015, to January 4, 2018. EXPOSURES: Exposures were defined as having any dispensed prescription for a histamine-2 receptor antagonist (H2RA), proton pump inhibitor (PPI), or antibiotic. MAIN OUTCOMES AND MEASURES: The main outcome was allergic disease, defined as the presence of food allergy, anaphylaxis, asthma, atopic dermatitis, allergic rhinitis, allergic conjunctivitis, urticaria, contact dermatitis, medication allergy, or other allergy. RESULTS: Of 792 130 children (395 215 [49.9%] girls) included for analysis, 60 209 (7.6%) were prescribed an H2RA, 13 687 (1.7%) were prescribed a PPI, and 131 708 (16.6%) were prescribed an antibiotic during the first 6 months of life. Data for each child were available for a median of 4.6 years. Adjusted hazard ratios (aHRs) in children prescribed H2RAs and PPIs, respectively, were 2.18 (95% CI, 2.04-2.33) and 2.59 (95% CI, 2.25-3.00) for food allergy, 1.70 (95% CI, 1.60-1.80) and 1.84 (95% CI, 1.56-2.17) for medication allergy, 1.51 (95% CI, 1.38-1.66) and 1.45 (95% CI, 1.22-1.73) for anaphylaxis, 1.50 (95% CI, 1.46-1.54) and 1.44 (95% CI, 1.36-1.52) for allergic rhinitis, and 1.25 (95% CI, 1.21-1.29) and 1.41 (95% CI, 1.31-1.52) for asthma. The aHRs after antibiotic prescription in the first 6 months of life were 2.09 (95% CI, 2.05-2.13) for asthma, 1.75 (95% CI, 1.72-1.78) for allergic rhinitis, 1.51 (95% CI, 1.38-1.66) for anaphylaxis, and 1.42 (95% CI, 1.34-1.50) for allergic conjunctivitis. CONCLUSIONS AND RELEVANCE: This study found associations between the use of acid-suppressive medications and antibiotics during the first 6 months of infancy and subsequent development of allergic disease. Acid-suppressive medications and antibiotics should be used during infancy only in situations of clear clinical benefit.

来源:JAMA Pediatr,查看原文。版权归原作者所有。

引用

  1. Mitre E, Susi A, Kropp LE, et al. Association Between Use of Acid-Suppressive Medications and Antibiotics During Infancy and Allergic Diseases in Early Childhood. JAMA Pediatr. 2018. PMID: 29610864. doi:10.1001/jamapediatrics.2018.0315

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。